Bazanella Monika, Maier Tanja V, Clavel Thomas, Lagkouvardos Ilias, Lucio Marianna, Maldonado-Gòmez Maria X, Autran Chloe, Walter Jens, Bode Lars, Schmitt-Kopplin Philippe, Haller Dirk
Chair of Nutrition and Immunology.
Research Unit Analytical Biogeochemistry, Helmholtz Center Munich, Oberschleißheim, Germany.
Am J Clin Nutr. 2017 Nov;106(5):1274-1286. doi: 10.3945/ajcn.117.157529. Epub 2017 Sep 6.
Early-life colonization of the intestinal tract is a dynamic process influenced by numerous factors. The impact of probiotic-supplemented infant formula on the composition and function of the infant gut microbiota is not well defined. We sought to determine the effects of a bifidobacteria-containing formula on the healthy human intestinal microbiome during the first year of life. A double-blind, randomized, placebo-controlled study of newborn infants assigned to a standard whey-based formula containing a total of 10 colony-forming units (CFU)/g of , , , subspecies (intervention), or to a control formula without bifidobacteria (placebo). Breastfed controls were included. Diversity and composition of fecal microbiota were determined by 16S ribosomal RNA gene amplicon sequencing, and metabolite profiles were analyzed by ultrahigh-performance liquid chromatography-mass spectrometry over a period of 2 y. Infants ( = 106) were randomly assigned to either the interventional ( = 48) or placebo ( = 49) group; 9 infants were exclusively breastfed throughout the entire intervention period of 12 mo. Infants exposed to bifidobacteria-supplemented formula showed decreased occurrence of and spp. associated with changes in lipids and unknown metabolites at month 1. Microbiota and metabolite profiles of intervention and placebo groups converged during the study period, and long-term colonization (24 mo) of the supplemented strains was not detected. Significant differences in microbiota and metabolites were detected between infants fed breast milk and those fed formula ( < 0.005) and between infants birthed vaginally and those birthed by cesarean delivery ( < 0.005). No significant differences were observed between infant feeding groups regarding growth, antibiotic uptake, or other health variables ( > 0.05). The supplementation of bifidobacteria to infant diet can modulate the occurrence of specific bacteria and metabolites during early life with no detectable long-term effects. This trial was registered at germanctr.de as DRKS00003660.
肠道的早期定植是一个受多种因素影响的动态过程。添加益生菌的婴儿配方奶粉对婴儿肠道微生物群的组成和功能的影响尚不明确。我们试图确定含双歧杆菌配方奶粉对健康人类生命第一年肠道微生物组的影响。一项针对新生儿的双盲、随机、安慰剂对照研究，将婴儿分为两组，一组喂食含有总共10个菌落形成单位（CFU）/克的长双歧杆菌、短双歧杆菌、婴儿双歧杆菌、假小链双歧杆菌亚种的标准乳清配方奶粉（干预组），另一组喂食不含双歧杆菌的对照配方奶粉（安慰剂组）。还纳入了母乳喂养的对照组。通过16S核糖体RNA基因扩增子测序确定粪便微生物群的多样性和组成，并在2年的时间里通过超高效液相色谱 - 质谱分析法分析代谢物谱。106名婴儿被随机分配到干预组（48名）或安慰剂组（49名）；9名婴儿在整个12个月的干预期内完全母乳喂养。接触添加双歧杆菌配方奶粉的婴儿在第1个月时与脂质和未知代谢物变化相关的嗜胆菌属和埃希氏菌属的出现频率降低。在研究期间，干预组和安慰剂组的微生物群和代谢物谱趋于一致，未检测到添加的双歧杆菌菌株的长期定植（24个月）。母乳喂养的婴儿和配方奶粉喂养的婴儿之间（P<0.005）以及顺产婴儿和剖宫产婴儿之间（P<0.005）在微生物群和代谢物方面存在显著差异。在生长、抗生素摄入或其他健康变量方面，婴儿喂养组之间未观察到显著差异（P>0.05）。在婴儿饮食中添加双歧杆菌可以在生命早期调节特定细菌和代谢物的出现，且没有可检测到的长期影响。该试验在germanctr.de上注册为DRKS00003660。
